These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27733785)

  • 1. Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis.
    Lidbury JA; Hoffmann AR; Fry JK; Suchodolski JS; Steiner JM
    Can J Vet Res; 2016 Oct; 80(4):302-308. PubMed ID: 27733785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
    Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
    Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.
    Valva P; Casciato P; Diaz Carrasco JM; Gadano A; Galdame O; Galoppo MC; Mullen E; De Matteo E; Preciado MV
    PLoS One; 2011; 6(8):e23218. PubMed ID: 21858035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
    Fontana RJ; Goodman ZD; Dienstag JL; Bonkovsky HL; Naishadham D; Sterling RK; Su GL; Ghosh M; Wright EC;
    Hepatology; 2008 Mar; 47(3):789-98. PubMed ID: 18175357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
    Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
    J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children.
    Nassef YE; Shady MM; Galal EM; Hamed MA
    Mem Inst Oswaldo Cruz; 2013 Nov; 108(7):887-93. PubMed ID: 24141960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possibility of Using ELF Score as Index for Hepatic Fibrosis Evaluation].
    Asano H
    Rinsho Byori; 2015 Jan; 63(1):78-83. PubMed ID: 26524882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    Puigvehí M; Hernández J; Broquetas T; Coll S; Garcia-Retortillo M; Cañete N; Giménez MD; Garcia M; Bory F; Salvadó M; Solà R; Carrión JA
    PLoS One; 2016; 11(12):e0164883. PubMed ID: 27984583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations of PIIINP aminopeptide in dogs with liver fibrosis.
    Glińska-Suchocka K; Orłowska A; Jankowski M; Kubiak K; Spużak J
    Pol J Vet Sci; 2016; 19(2):365-9. PubMed ID: 27487511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease.
    Kawashiri SY; Origuchi T; Umeda M; Nishino A; Shimizu T; Fukui S; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Maeda T; Kawano M; Yamamoto M; Izumi Y; Kawakami A
    Arthritis Res Ther; 2018 Dec; 20(1):277. PubMed ID: 30547825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Serum Markers of Hepatic Fibrosis in Equids.
    Potier JFN; Durham AE; Modi R; Rosenberg W; Dash SA
    J Equine Vet Sci; 2023 Dec; 131():104937. PubMed ID: 37816414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis.
    Zheng M; Cai WM; Weng HL; Liu RH
    World J Gastroenterol; 2002 Dec; 8(6):1073-6. PubMed ID: 12439928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.
    Abignano G; Blagojevic J; Bissell LA; Dumitru RB; Eng S; Allanore Y; Avouac J; Bosello S; Denton CP; Distler O; Ferraccioli G; Jordan S; Matucci-Cerinic M; Ong V; Messenger M; Hutchinson M; Buch MH; Emery P; Del Galdo F
    Rheumatology (Oxford); 2019 Feb; 58(2):254-259. PubMed ID: 30239834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.
    Rath T; Roderfeld M; Güler C; Wenzel C; Graf J; Beitinger F; Roeb E; Zachoval R
    Scand J Gastroenterol; 2011 Nov; 46(11):1369-80. PubMed ID: 21905976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.
    Omran D; Yosry A; Darweesh SK; Nabeel MM; El-Beshlawey M; Saif S; Fared A; Hassany M; Zayed RA
    Clin Exp Med; 2018 Feb; 18(1):45-50. PubMed ID: 28567544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
    Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.
    Fernandes FF; Ferraz ML; Andrade LE; Dellavance A; Terra C; Pereira G; Pereira JL; Campos F; Figueiredo F; Perez RM
    J Clin Gastroenterol; 2015 Mar; 49(3):235-41. PubMed ID: 24714186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
    Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
    Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.